Orchid Pharma details growth, ESG initiatives in sustainability report

Orchid Pharma Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2024-25 to the stock exchanges on August 26, 2025. The report, which also forms part of the company’s annual report, details Orchid Pharma's efforts in environmental, social, and governance (ESG) areas. The company reported a turnover of INR 921.93 Cr and a net worth of INR 1324.00 Cr for FY 2024-25. Manufacturing of Cephalosporin API & FDF constitutes 98.61% of its turnover.

Key initiatives include a Zero Liquid Discharge (ZLD) system across 100% of its operational unit, resulting in 128,845 liters of fresh water consumption reduced. The company also utilizes renewable energy, achieving 69% of its total energy from sources like solar and wind, leading to a reduction of 47,081 tons of CO2 emissions. These efforts align with the company's goal to achieve over 95% renewable energy usage by 2045.

Orchid Pharma reported a diverse employee base with 1,051 total employees in FY 2024-25, of whom 96% are male and 4% are female. The company has implemented comprehensive policies on product quality and safety, waste management, R&D investments, and regulatory compliance. It actively engages with stakeholders to address concerns and ensure ethical business practices.